| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9674d1bb50f49718f941e42d1d79c834 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2014-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a308d0ef733e68575ae3ab0277aedd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a136630ba728ca89128693b19c5f437c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09cc6cfb4f647ba7f33f836f05d95fb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c10695e29c0e613ab64267b1a8d21278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46b4ced4c55f9d3f0a26279e2843236e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12041a91b01cea96cb4c4f23879fcfef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86841300496ed7794087ce203d66cdd5 |
| publicationDate |
2015-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20150112385-A |
| titleOfInvention |
A New Antibody Fragment Derived from Cetuximab |
| abstract |
The present invention relates to a novel protein capable of specifically binding to EGFR (Epidermal Growth Factor receptor) or a nucleic acid molecule encoding the same. The present invention also relates to a pharmaceutical composition for cancer therapy or a composition for cancer diagnosis comprising the protein. The nucleic acid molecule encoding the antibody fragment of the present invention exhibits a protein expression rate of 2 to 3 times or more, despite the reverse order of the domains in the conventional scFv, and the antibody fragment of the present invention exhibits remarkably improved antigen binding ability and cell line binding ability Respectively. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200098831-A |
| priorityDate |
2014-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |